Askiel Bruno, MD
Neurology · Augusta, GANPI 1770505737
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 67.1% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $6,825 and has fallen 95.5% since, to $310 in 2025.
Across 100 payments — averaging $92.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Biogen$1K
- Johnson & Johnson$185
- Janssen Research & Development, LLC$149
- Stryker$146
- UCB, Inc.$145
- plus $1K from 22 others
Across 27 payments — averaging $9850.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$162K
- Janssen Research & Development, LLC$104K
What the payments were for
- Speaking & faculty fees$5,00054%
- Travel & lodging$1,74519%
- Food & beverage$2,54027%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 13 | $6,229 |
| Biogen | 12 | $1,403 |
| Johnson & Johnson(2 entities) | 6 | $185 |
| Janssen Research & Development, LLC | 1 | $149 |
| Stryker | 1 | $146 |
| UCB, Inc. | 6 | $145 |
| AbbVie(2 entities) | 7 | $129 |
| Sunovion Pharmaceuticals Inc. | 15 | $120 |
| SK Life Science, Inc. | 4 | $117 |
| AstraZeneca(2 entities) | 4 | $97 |
| Jazz Pharmaceuticals Inc. | 5 | $95 |
| E.r. Squibb & Sons, L.L.C. | 4 | $70 |
| Portola Pharmaceuticals, LLC | 3 | $62 |
| Chiesi USA, Inc. | 2 | $50 |
| Genentech USA, Inc. | 3 | $37 |
| Boston Scientific | 1 | $37 |
| Amgen | 2 | $36 |
| Greenwich Biosciences, Inc. | 1 | $23 |
| Ceribell, Inc. | 1 | $20 |
| Neurelis, Inc. | 1 | $20 |
| Livanova USA, Inc. | 1 | $17 |
| Novartis | 1 | $17 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Octapharma USA, Inc. | 1 | $14 |
| Pfizer | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $13 |
| Tanabe Pharma America, Inc. | 1 | $12 |
| Natus Medical Incorporated | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMPLATZER Occluders$3,118
- Amplatzer Cardiac Plug$2,946
- TREVO$146
How this compares
$9,284 in reported general payments places this provider in the 75th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Augusta
- John MorganAugusta$715K
- Alexis ShaeferAugusta$279K
- Kapil SethiAugusta$52K
- Colin McLeodAugusta$49K
- Debra Moore-HillAugusta$48K
- Mitzi WilliamsSmyrna$1.4M
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.